The company's increased debt, decreased revenue, and negativ...
The company's increased debt, decreased revenue, and negative EBIT and free cash flow are concerning factors. The balance sheet currently appears weak and poses risks to shareholders, necessitating improvements over time.
Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Is Carrying A Fair Bit Of Debt
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment